BSD Medical Corporation (NASDAQ:BSDM) (BSD or the Company) today reported publication of an article on BSD's pioneering development of sophisticated technology to improve the delivery of heat therapy for the treatment of certain cancerous tumors. The article, "Interstitial microwave transition from hyperthermia to ablation: Historical perspectives and current trends in thermal therapy," which was authored by TP Ryan, PF Turner, and B Hamilton, was published in the "International Journal of Hyperthermia," the premier worldwide journal for original heat therapy research. PF Turner is BSD's Chief Technology Officer and B Hamilton is one of BSD's engineers. T Ryan is a leading researcher in heat therapy technology. BSD has been designing thermal therapy systems for 32 years and has obtained several pioneering patents for the devices, techniques, and methodology used in heat therapy. The article demonstrates the benefits in using the BSD's advanced synchronous phased array technology for ablation therapy.
“Interstitial microwave transition from hyperthermia to ablation: Historical perspectives and current trends in thermal therapy”
The article reviews the evolution of heat therapy for the treatment of cancer and traces the transition of BSD's patented phased array technology from hyperthermia applications to utilization in BSD's current ablation therapy technology. The phased array technology and techniques reviewed in the publication were developed by the Company to improve the delivery of heat therapies by directly targeting heating to the tumor. This technology was utilized in the design of the BSD-500 interstitial phased arrays and the BSD-2000 Hyperthermia System to provide uniform preferential heating throughout the central region of a tumor when using two or more antennas.
The Company utilized the same advanced synchronous phased array designs in the development of the MicroThermX Microwave Ablation System (MTX-180) to provide improved targeting of the ablation therapy delivered to the patient (patents pending). These designs allow the MTX-180 to provide larger and more uniform zones of ablation during a single procedure. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System for ablation of soft tissue.
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients